308 related articles for article (PubMed ID: 29626509)
1. Manipulation of spray-drying conditions to develop dry powder particles with surfaces enriched in hydrophobic material to achieve high aerosolization of a hygroscopic drug.
Momin MAM; Tucker IG; Doyle CS; Denman JA; Das SC
Int J Pharm; 2018 May; 543(1-2):318-327. PubMed ID: 29626509
[TBL] [Abstract][Full Text] [Related]
2. Co-spray drying of hygroscopic kanamycin with the hydrophobic drug rifampicin to improve the aerosolization of kanamycin powder for treating respiratory infections.
Momin MAM; Tucker IG; Doyle CS; Denman JA; Sinha S; Das SC
Int J Pharm; 2018 Apr; 541(1-2):26-36. PubMed ID: 29458207
[TBL] [Abstract][Full Text] [Related]
3. The influence of storage relative humidity on aerosolization of co-spray dried powders of hygroscopic kanamycin with the hydrophobic drug rifampicin.
Momin MAM; Tucker IG; Das SC
Drug Dev Ind Pharm; 2019 Jul; 45(7):1205-1213. PubMed ID: 30990097
[TBL] [Abstract][Full Text] [Related]
4. Protection of hydrophobic amino acids against moisture-induced deterioration in the aerosolization performance of highly hygroscopic spray-dried powders.
Yu J; Chan HK; Gengenbach T; Denman JA
Eur J Pharm Biopharm; 2017 Oct; 119():224-234. PubMed ID: 28655664
[TBL] [Abstract][Full Text] [Related]
5. L-Leucine as an excipient against moisture on in vitro aerosolization performances of highly hygroscopic spray-dried powders.
Li L; Sun S; Parumasivam T; Denman JA; Gengenbach T; Tang P; Mao S; Chan HK
Eur J Pharm Biopharm; 2016 May; 102():132-41. PubMed ID: 26970252
[TBL] [Abstract][Full Text] [Related]
6. Dry powder formulation of kanamycin with enhanced aerosolization efficiency for drug-resistant tuberculosis.
Momin MAM; Sinha S; Tucker IG; Doyle C; Das SC
Int J Pharm; 2017 Aug; 528(1-2):107-117. PubMed ID: 28583333
[TBL] [Abstract][Full Text] [Related]
7. Effects of the antibiotic component on in-vitro bacterial killing, physico-chemical properties, aerosolization and dissolution of a ternary-combinational inhalation powder formulation of antibiotics for pan-drug resistant Gram-negative lung infections.
Mangal S; Huang J; Shetty N; Park H; Lin YW; Yu HH; Zemlyanov D; Velkov T; Li J; Zhou QT
Int J Pharm; 2019 Apr; 561():102-113. PubMed ID: 30797863
[TBL] [Abstract][Full Text] [Related]
8. Carrier-free combination dry powder inhaler formulation of ethionamide and moxifloxacin for treating drug-resistant tuberculosis.
Momin MAM; Sinha S; Tucker IG; Das SC
Drug Dev Ind Pharm; 2019 Aug; 45(8):1321-1331. PubMed ID: 31014129
[TBL] [Abstract][Full Text] [Related]
9. Surface Composition and Aerosolization Stability of an Inhalable Combinational Powder Formulation Spray Dried Using a Three-Fluid Nozzle.
Shetty N; Zhang Y; Park H; Zemlyanov D; Shah D; He A; Ahn P; Mutukuri TT; Chan HK; Zhou QT
Pharm Res; 2020 Oct; 37(11):219. PubMed ID: 33037471
[TBL] [Abstract][Full Text] [Related]
10. Aerosolization characteristics of dry powder inhaler formulations for the excipient enhanced growth (EEG) application: effect of spray drying process conditions on aerosol performance.
Son YJ; Worth Longest P; Hindle M
Int J Pharm; 2013 Feb; 443(1-2):137-45. PubMed ID: 23313343
[TBL] [Abstract][Full Text] [Related]
11. Improved Aerosolization Stability of Inhalable Tobramycin Powder Formulation by Co-Spray Drying with Colistin.
Pathak V; Park H; Zemlyanov D; Bhujbal SV; Ahmed MU; Azad MAK; Li J; Zhou QT
Pharm Res; 2022 Nov; 39(11):2781-2799. PubMed ID: 35915320
[TBL] [Abstract][Full Text] [Related]
12. Improved Physical Stability and Aerosolization of Inhalable Amorphous Ciprofloxacin Powder Formulations by Incorporating Synergistic Colistin.
Shetty N; Ahn P; Park H; Bhujbal S; Zemlyanov D; Cavallaro A; Mangal S; Li J; Zhou QT
Mol Pharm; 2018 Sep; 15(9):4004-4020. PubMed ID: 30028947
[TBL] [Abstract][Full Text] [Related]
13. Phospholipid-based pyrazinamide spray-dried inhalable powders for treating tuberculosis.
Eedara BB; Tucker IG; Das SC
Int J Pharm; 2016 Jun; 506(1-2):174-83. PubMed ID: 27091294
[TBL] [Abstract][Full Text] [Related]
14. Effects of Surface Composition on the Aerosolisation and Dissolution of Inhaled Antibiotic Combination Powders Consisting of Colistin and Rifampicin.
Wang W; Zhou QT; Sun SP; Denman JA; Gengenbach TR; Barraud N; Rice SA; Li J; Yang M; Chan HK
AAPS J; 2016 Mar; 18(2):372-84. PubMed ID: 26603890
[TBL] [Abstract][Full Text] [Related]
15. Bedaquiline containing triple combination powder for inhalation to treat drug-resistant tuberculosis.
Rangnekar B; Momin MAM; Eedara BB; Sinha S; Das SC
Int J Pharm; 2019 Oct; 570():118689. PubMed ID: 31513868
[TBL] [Abstract][Full Text] [Related]
16. Correlations between surface composition and aerosolization of jet-milled dry powder inhaler formulations with pharmaceutical lubricants.
Mangal S; Park H; Nour R; Shetty N; Cavallaro A; Zemlyanov D; Thalberg K; Puri V; Nicholas M; Narang AS; Zhou QT
Int J Pharm; 2019 Sep; 568():118504. PubMed ID: 31299339
[TBL] [Abstract][Full Text] [Related]
17. How Much Surface Coating of Hydrophobic Azithromycin Is Sufficient to Prevent Moisture-Induced Decrease in Aerosolisation of Hygroscopic Amorphous Colistin Powder?
Zhou QT; Loh ZH; Yu J; Sun SP; Gengenbach T; Denman JA; Li J; Chan HK
AAPS J; 2016 Sep; 18(5):1213-1224. PubMed ID: 27255350
[TBL] [Abstract][Full Text] [Related]
18. Nano spray-dried pyrazinamide-L-leucine dry powders, physical properties and feasibility used as dry powder aerosols.
Kaewjan K; Srichana T
Pharm Dev Technol; 2016; 21(1):68-75. PubMed ID: 25331092
[TBL] [Abstract][Full Text] [Related]
19. Investigation of the Changes in Aerosolization Behavior Between the Jet-Milled and Spray-Dried Colistin Powders Through Surface Energy Characterization.
Jong T; Li J; Morton DA; Zhou QT; Larson I
J Pharm Sci; 2016 Mar; 105(3):1156-63. PubMed ID: 26886330
[TBL] [Abstract][Full Text] [Related]
20. Understanding the Impacts of Surface Compositions on the In-Vitro Dissolution and Aerosolization of Co-Spray-Dried Composite Powder Formulations for Inhalation.
Mangal S; Xu R; Park H; Zemlyanov D; Shetty N; Lin YW; Morton D; Chan HK; Li J; Zhou QT
Pharm Res; 2018 Nov; 36(1):6. PubMed ID: 30406281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
